<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903588</url>
  </required_header>
  <id_info>
    <org_study_id>S-2018-2</org_study_id>
    <nct_id>NCT03903588</nct_id>
  </id_info>
  <brief_title>The Heidelberg Engineering SPECTRALIS Macular Precision and Agreement Study</brief_title>
  <official_title>The Heidelberg Engineering SPECTRALIS Macular Precision and Agreement Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Engineering GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg Engineering GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical study that will be conducted at one clinical site located in&#xD;
      the United States to assess two grids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Layer Thickness</measure>
    <time_frame>5 months</time_frame>
    <description>Measurement of the thickness of Retinal layers thickness to assess 2 grids</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">86</enrollment>
  <condition>Retinal Layer Separation</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Eyes that have been diagnoses with Glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinal Disease</arm_group_label>
    <description>Eyes that have been diagnoses with a Retinal Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Imaging of the Retina</description>
    <arm_group_label>Glaucoma</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Retinal Disease</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normals, Glaucoma and Retinal Subjects as per Inclusion/Exclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion All Eye Populations&#xD;
&#xD;
          -  Age 22 years or older&#xD;
&#xD;
          -  Able and willing to undergo the test procedures, sign informed consent, and follow&#xD;
             instructions&#xD;
&#xD;
          -  Able to fixate&#xD;
&#xD;
          -  Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.&#xD;
&#xD;
          -  Axial length ≤ 26.0 mm&#xD;
&#xD;
        Exclusion All Eye Populations&#xD;
&#xD;
          -  Subjects unable to read or write&#xD;
&#xD;
          -  Ocular media is not sufficiently clear to obtain acceptable quality images&#xD;
&#xD;
          -  Physical inability to be properly positioned at the study devices or eye exam&#xD;
             equipment&#xD;
&#xD;
        Inclusion Normal Population&#xD;
&#xD;
          -  Eyes without prior intraocular surgery bilaterally (except cataract surgery and LASIK)&#xD;
&#xD;
          -  Intraocular pressure ≤ 21mmHg&#xD;
&#xD;
          -  Best corrected visual acuity ≥ 20/40&#xD;
&#xD;
          -  Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim&#xD;
             with respect to color and shape, and clinically normal appearing posterior pole&#xD;
&#xD;
          -  Both eyes must be determined to be normal, as determined by an investigator&#xD;
&#xD;
        Exclusion Normal Population&#xD;
&#xD;
          -  Subjects with vitreal, retinal or choroidal conditions or disease of the optic nerve.&#xD;
             Subjects may have diabetes but cannot have diabetic retinopathy.&#xD;
&#xD;
          -  History of glaucoma (not including family history)&#xD;
&#xD;
          -  Unreliable visual field as determined by the manufacturer's recommendations of:&#xD;
&#xD;
        Fixation losses &gt; 20%, False Positives &gt; 33%, False Negatives &gt; 15%&#xD;
&#xD;
        -Visual field defects consistent with glaucomatous optic nerve damage based on at least one&#xD;
        of the following two findings: On pattern deviation (PD), there exists a cluster of 3 or&#xD;
        more points in an expected location of the visual field depressed below the 5% level, at&#xD;
        least 1 of which is depressed below the 1% level; Glaucoma hemi-field test &quot;outside normal&#xD;
        limits&quot;&#xD;
&#xD;
        Inclusion Glaucoma Population&#xD;
&#xD;
          -  Subjects who have a glaucoma diagnosis without prior non-glaucoma related intra-ocular&#xD;
             surgery (except cataract surgery and LASIK)&#xD;
&#xD;
          -  Glaucomatous optic nerve damage as evidenced by any of the following optic disc or&#xD;
             retinal nerve fiber layer structural abnormalities:&#xD;
&#xD;
        Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the&#xD;
        inferior or superior poles with or without disc hemorrhage; Localized abnormalities of the&#xD;
        peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or&#xD;
        Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue&#xD;
&#xD;
          -  Visual field defects consistent with glaucomatous optic nerve damage based on at least&#xD;
             one of the following two findings:&#xD;
&#xD;
          -  On pattern deviation (PD), there exists a cluster of 3 or more points in an expected&#xD;
             location of the visual field depressed below the 5% level, at least 1 of which is&#xD;
             depressed below the 1% level; Glaucoma hemi-field test &quot;outside normal limits.&quot;&#xD;
&#xD;
          -  Best corrected visual acuity ≥ 20/40&#xD;
&#xD;
        Exclusion Glaucoma Population&#xD;
&#xD;
          -  Subjects with presence of any ocular pathology other than Glaucoma in the study eye&#xD;
             (cataracts are acceptable)&#xD;
&#xD;
          -  Unreliable visual field as determined by the manufacturer's recommendations of:&#xD;
&#xD;
        Fixation losses &gt; 20%, False Positives &gt; 33%, False Negatives &gt; 15%&#xD;
&#xD;
        Inclusion Retina Population&#xD;
&#xD;
          -  Subjects who have a retinal condition diagnosis without prior non-retinal related&#xD;
             intra-ocular surgery (except cataract surgery and LASIK).&#xD;
&#xD;
          -  Intraocular pressure ≤21mmHg&#xD;
&#xD;
          -  Best corrected visual acuity ≥20/400&#xD;
&#xD;
        Exclusion Retina Population&#xD;
&#xD;
        -Subjects with presence of any ocular pathology other than retinal conditions in the study&#xD;
        eye (cataracts are acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State University of New York Optometry School</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

